Par’Immune is a French company leveraging 20 years legacy of academic research on a parasite-derived protein, P28GST, to develop therapeutic strategies toward aggressive inflammatory autoimmune diseases.
Besides its safety profile validated in several clinical trials, the immunomodulatory potential of P28GST has been demonstrated in preclinical models of inflammatory diseases. Our drug candidate is under evaluation in a Phase 2a clinical trial in Crohn’s disease.